Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things (“IoT”), is pleased to announce that its portfolio company, FVRVS Limited (“FundamentalVR”), has secured a further £0.4 million contract with an existing client, one of the world’s leading pharmaceutical companies (the “Client”), to support training and adoption of its Ocular Gene Therapy product.
Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things (“IoT”), is pleased to announce that its portfolio company, FVRVS Limited (“FundamentalVR”), has secured a three year contract worth a minimum of £0.9 million from a new client, which is a global medical device company (the “Client”), to accelerate the adoption, and subsequent safe and compliant use, of the Client’s product.